Most Recent
J&J slams class action over cold and flu medications
Johnson & Johnson has slammed a class action over allegedly ineffective cold and flu medications, telling a judge it has "real concerns" with how the case has been framed.
Developer’s challenge to NSW Ports decision an abuse of process, court told
Mayfield Development is barred from bringing claims already traversed in a competition case by the ACCC that was thrown out by a court, NSW Ports has told an appeals court.
‘Monumental waste of time’: Judge won’t hear summary dismissal bid in postgrads class action
A judge is not ready to hear a bid to summarily dismiss a "long and tortured" case alleging University of Sydney postgraduate students were underpaid, calling it a "monumental waste of time".
Construction PRO
Lady Fairfax trust can’t escape surcharge land tax, court finds
A judge has found two major Sydney residential developments that are part of the estate of the late Lady Mary Fairfax cannot dodge surcharge land tax.
Construction PRO
Mineralogy can’t get more discovery from CITIC in fight over Sino Iron mine
Mineralogy has lost another bid for further discovery from engineering firm CITIC a month before trial kicks off in their fight over the Sino Iron project in Western Australia's Pilbara region.
Port of Newcastle can’t move wharf dispute with Glencore out of state court
The Port of Newcastle has lost its bid to move a lawsuit filed by Glencore Coal over $870,000 in alleged overcharged shipping fees to the Federal Court. 
Noumi’s ex-boss might take stand in ASIC case over inventory disclosures
The former managing director and CEO of food company Noumi may give evidence at trial in the corporate regulator's case next year.
Phoslock class action doesn’t have to bear costs from competing case
A judge has found a shareholder class action against water treatment company Phoslock and auditor KPMG should not bear the costs incurred by a competing case for preliminary discovery.
Bayer can’t get High Court to hear Xarelto patent fight
The High Court won't hear Bayer's appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company's claim the decision has "profound" consequences for drug R&D.